CoronaryAtlas logo
CoronaryAtlas
Very-Low-Density Lipoprotein
Pathway / Lipid retention & oxidation

Very-Low-Density Lipoprotein

lipoprotein

VLDL, an apoB-containing atherogenic lipoprotein, accumulates in the arterial intima where it undergoes oxidative modification, initiating atherosclerotic plaque formation.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleApoB-containing atherogenic particle; retained in arterial intima and subject to oxidative modification.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
50
A — assay feasibility
82
E — evidence strength
46
T1DI (composite)
22
Specificity differential (R−C)+17
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 2/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 4 supporting references. See the discrimination table for all markers.

Assay & specimen

Specialized reference method
Specimen
Serum or plasma (EDTA)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
NMR lipoprotein particle analysis or density-gradient ultracentrifugation
Reagent / substrate
No chemical reagent — NMR spectral deconvolution of lipid methyl signals (or ultracentrifugal separation by density)
Platform
NMR (LabCorp NMR LipoProfile) / analytical ultracentrifuge
Turnaround · availability
Send-out · Specialized reference lab

Literature evidence(21)